Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for metastatic gastrointestinal stromal tumor after imatinib failure or sunitinib intolerance
ChiCTR1800020407Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastrointestinal stromal tumor (GIST), sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall survival. Started Jan 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR1800020407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020407.